Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials

  title={Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials},
  author={Franklin Rosenfeldt and Steven Joseph Haas and Henry Krum and Afif Hadj and K Ng and Jee-Yoong Leong and Gerald F. Watts},
  journal={Journal of Human Hypertension},
Our objective was to review all published trials of coenzyme Q10 for hypertension, assess overall efficacy and consistency of therapeutic action and side effect incidence. Meta-analysis was performed in 12 clinical trials (362 patients) comprising three randomized controlled trials, one crossover study and eight open label studies. In the randomized controlled trials (n=120), systolic blood pressure in the treatment group was 167.7 (95% confidence interval, CI: 163.7–171.1) mm Hg before, and… 
A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome.
The data suggest that coenzyme Q(10) is not currently indicated as adjunctive antihypertensive treatment for patients with the metabolic syndrome whose BP control is inadequate, despite regular antihyertensive therapy.
The Effects of Coenzyme Q10 Supplementation on Blood Pressures Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials
CoQ10 supplementation may result in reduction in SBP levels, but did not affect DBP levels among patients with metabolic diseases, and additional prospective studies regarding the effect of CoQ10 supplements on blood pressure in patientsWith metabolic diseases are necessary.
Coenzyme Q10 for statin-induced myopathy : a systematic review
Three studies were excluded from the review due to reasons relating to study design and outcomes measured (Table 3.8), but the summary of these two abstracts shows that they may have been relevant for inclusion in this review.
A Randomized , Double-Blind , Placebo-Controlled Crossover Study of Coenzyme Q 10 Therapy in Hypertensive Patients With the Metabolic Syndrome
The metaanalysis was limited by the inclusion of studies which were open-labeled and not placebo-controlled, and there were considerable differences in patient populations with respect to age, underlying disease and comorbidities, coenzyme Q10 dose and duration, and use of concomitant antihypertensive therapy between the trials.
Coenzyme Q 10 in cardiovascular disease
There is promising evidence of a beneficial effect of CoQ10 when given alone or in addition to standard therapies in hypertension and in heart failure, but less extensive evidence in ischemic heart disease.
Coenzyme Q10 to treat and prevent heart disease
The specific form of CoQ10 used in the Q-SYMBIO and KISEL-10 studies addresses previous concerns regarding issues of product quality, safety and variable efficiencies.
Can Coenzyme Q10 Lead to Improvement of Essential Hypertension?: A Long-Term Case Study
Many hypertensive patients are continuously prescribed various antihypertensive drugs despite the undesirable side effects such as nausea, dizziness, and vertigo. To decrease the use of


Randomized, Double-Blind, Placebo- Controlled Trial of Coenzyme Q10 in Isolated Systolic Hypertension
The results suggest CoQ may be safely offered to hypertensive patients as an alternative treatment option, and the antihypertensive effectiveness of CoQ, an over-the-counter nutritional supplement, is evaluated.
Coenzyme Q10 in essential hypertension.
Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease
It is indicated that treatment with coenzyme q10 decreases blood pressure possibly by decreasing oxidative stress and insulin response in patients with known hypertension receiving conventional antihypertensive drugs.
Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes
Results show that CoQ supplementation may improve blood pressure and long-term glycaemic control in subjects with type 2 diabetes, but these improvements were not associated with reduced oxidative stress, as assessed by F2-isoprostanes.
Bioenergetics in clinical medicine. Studies on coenzyme Q10 and essential hypertension.
A clinical benefit from administration of CoQ10 to patients with essential hypertension could be based upon correcting a deficiency in bioenergetics, and point to possible combination treatments with a form of Co Q and anti-hypertensive drugs.
Coenzyme Q10 in health and disease
Positive clinical and haemodynamic effects of oral Q10 supplementation have been observed in double-blind trials, especially in chronic heart failure, and these effects should be further examined.
Bioenergetics in clinical medicine. XVI. Reduction of hypertension in patients by therapy with coenzyme Q10.
It is considered that (1) the mechanism of reduction of elevated blood pressures by CoQ10 is based upon normalization or autoregulation of peripheral resistance rather than cardiac regulation, and (2) the therapeutic activity of Co Q10 is not pharmacodynamic, but results from a translational increase in levels of CoQ 10-enzymes in vascular tissue during ca.